Blue Cross Blue Shield/Blue Care Network of Michigan Medication Authorization Request Form



Nonprofit corporations and independent licensees of the Blue Cross and Blue Shield Association

This form is to be used by participating physicians to obtain coverage for **drugs covered under the medical benefit**. For <u>commercial members only</u>, please complete this form and submit via fax to 1-877-325-5979. If you have any questions regarding this process, please contact BCBSM Provider Relations and Servicing or the Medical Drug Helpdesk at 1-800-437-3803 for assistance.

PATIENT INFORMATION		PHYSICIAN INFORMATION		
Name		Name		
ID Number		Specialty		
D.O.B. /_/	MM/DD/YYYY	Address		
Diagnosis		City /State/Zip		
Drug Name Entyvio		Phone: Fax:		
Dose and Quantity		NPI		
Directions		Contact Person		
Date of Service(s)		Contact Person Phone / Ext.		
TEP 1: DISEASE STATE INFORMATION	N			
Required Demographic Informa	tion•			
Patient Weight:				
Patient Height:		,		
1 uttentHeight.	jiinches			
Is this member's FEP coverage print If primary, continue with If secondary, an authoric determination of benefit Site of Care: A. At what location will the mean Improvement In Outpatient hospital infusion receive this medication in	mary or secondary coverage question set. zation is not needed throug and additional information where the receiving the requirements on center. Please provide the a hospital outpatient setting	gh this process. Please contact the member's primary coverage for on. ested medication? a ted ambulatory infusion center. he name of the infusion center and rationale why the patient must hig.		
Other. Please specify.				
Criteria Questions: 1. What is the patient's diagnosis ☐ Crohn's Disease (CD) ☐ Ulcerative Colitis (UC) ☐ Other diagnosis (please specific please specifi				
 Does the prescriber a gree to a c Yes □ No 	dminister Entyvio within the	eFDA labeled maintenance dose of 300mg every 8 weeks?		
Select answer below: ☐ Yes (please specify): ☐ No *DMARD includes: Actemra, Cimzia	☐ Yes (please specify):			
Stelara, Taltz, Tremfya, and Xeljanz 4. Has the patient been on Entyv	io therapy continuously for	the last 3 months, excluding samples?		

Please select answer below:

□ NO – this is INITIATION of thempy, please answer the following questions:

		Is the patient's condition moderate to severely active? Has the patient experienced an inadequate response, into Yes No	Yes No No plerance or contraindication to at least one conventional therapy?	
Ţ	■ YES – this is a PA renewal for CONTINUATION of therapy, please answer the following question: a. Has the patient undergone re-evaluation to show improvement or stabilization in their condition a fter at least 14 weeks of treatment? ■ Yes ■ No			
Chart notes are required for the processing of all requests. Please add any other supporting medical information necessary for our review (required) Coverage will not be provided if the prescribing physician's signature and date are not reflected on this document.				
Request for expedited review: I certify that applying the standard review time frame may seriously jeopardize the life or health of the member or the member's ability to regain maximum function				
Physician's Nan		Physician Signature	Date	
Step 2:		rm Completely Filled Out	☐ Attach test results	
Step 3:	■ Pro	By Fax: BCBSM Specialty Pharmacy Mailbox	By Mail: BCBSM Specialty Pharmacy Program	
Step 2: Checklist	☐ Foi	rm Completely Filled Out ovide chart notes	☐ Attach test results	
step 3:		By Fax: BCBSM Specialty Pharmacy Mailbox	By Mail: BCBSM Specialty Pharmacy Program	

1-877-325-5979

Submit

P.O. Box 312320, Detroit, MI 48231-2320